BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 2359181)

  • 1. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
    Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
    Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
    Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.
    Lage JM; Bauer WC; Kelley DR; Ratliff TL; Catalona WJ
    J Urol; 1986 May; 135(5):916-9. PubMed ID: 3959240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-Guérin-treated superficial bladder cancer: correlation of morphology with immunophenotyping.
    Leong AS; Wannakrairot P; Jose J; Milios J
    J Pathol; 1990 Sep; 162(1):35-41. PubMed ID: 2231190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.
    Peuchmaur M; Benoit G; Vieillefond A; Chevalier A; Lemaigre G; Martin ED; Jardin A
    Urol Res; 1989; 17(5):299-303. PubMed ID: 2683316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
    Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
    Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
    Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
    Hillyard RW; Ladaga L; Schellhammer PF
    J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.